Institution
Hebron University
Education•Hebron, Palestinian Territory•
About: Hebron University is a education organization based out in Hebron, Palestinian Territory. It is known for research contribution in the topics: Population & Cancer. The organization has 2714 authors who have published 4180 publications receiving 163736 citations.
Topics: Population, Cancer, Breast cancer, Medicine, Metastatic breast cancer
Papers published on a yearly basis
Papers
More filters
Food and Drug Administration1, University of Colorado Boulder2, Memorial Sloan Kettering Cancer Center3, University of California, San Francisco4, Mayo Clinic5, University of Turin6, Ohio State University7, Brigham and Women's Hospital8, Karolinska University Hospital9, University of Texas MD Anderson Cancer Center10, Bristol-Myers Squibb11, AstraZeneca12, Stanford University13, Children's National Medical Center14, University of Duisburg-Essen15, Hebron University16, Vita-Salute San Raffaele University17, Merck & Co.18, University of Texas Southwestern Medical Center19, European Medicines Agency20, Johns Hopkins University21, Fred Hutchinson Cancer Research Center22, Columbia University Medical Center23, Maastricht University Medical Centre24, Columbia University25, Center for Drug Evaluation and Research26, University of Colorado Denver27, Cornell University28
TL;DR: Given the success of oncogene‐targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes.
117 citations
Strathclyde Institute of Pharmacy and Biomedical Sciences1, Karolinska University Hospital2, Hebron University3, University of KwaZulu-Natal4, Wellington Management Company5, Universidade Federal de Minas Gerais6, Turkish Ministry of Health7, University of Vienna8, University of Manchester9, Utrecht University10, Stockholm County Council11, Ministry of Health (Malaysia)12, Green Templeton College13, Vilnius University14, Horizon Blue Cross Blue Shield of New Jersey15, Karolinska Institutet16, Trinity College, Dublin17, Nelson Mandela Metropolitan University18, Chongqing Jiaotong University19
TL;DR: The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines, as well as develop exemplar models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure.
Abstract: Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.
116 citations
Harvard University1, University of Brescia2, Newcastle University3, Kuwait University4, Université de Montréal5, Cincinnati Children's Hospital Medical Center6, Boston Children's Hospital7, Indiana University8, Ain Shams University9, Hebron University10, Northwestern University11, Carolinas Medical Center12, University of California, San Francisco13, University of Rome Tor Vergata14, University of Utah15, Lund University16
TL;DR: In this paper, the authors investigated the molecular basis for phenotypic diversity presented in patients with various RAG1 mutations, and demonstrated correlation between defective recombination activity of hRAG1 mutant proteins and severity of the clinical and immunologic phenotype.
Abstract: Background The recombination-activating gene (RAG) 1/2 proteins play a critical role in the development of T and B cells by initiating the VDJ recombination process that leads to generation of a broad T-cell receptor (TCR) and B-cell receptor repertoire. Pathogenic mutations in the RAG1/2 genes result in various forms of primary immunodeficiency, ranging from T − B − severe combined immune deficiency to delayed-onset disease with granuloma formation, autoimmunity, or both. It is not clear what contributes to such heterogeneity of phenotypes. Objective We sought to investigate the molecular basis for phenotypic diversity presented in patients with various RAG1 mutations. Methods We have developed a flow cytometry–based assay that allows analysis of RAG recombination activity based on green fluorescent protein expression and have assessed the induction of the Ighc locus rearrangements in mouse Rag1 −/− pro-B cells reconstituted with wild-type or mutant human RAG1 (hRAG1) using deep sequencing technology. Results Here we demonstrate correlation between defective recombination activity of hRAG1 mutant proteins and severity of the clinical and immunologic phenotype and provide insights on the molecular mechanisms accounting for such phenotypic diversity. Conclusions Using a sensitive assay to measure the RAG1 activity level of 79 mutations in a physiologic setting, we demonstrate correlation between recombination activity of RAG1 mutants and the severity of clinical presentation and show that RAG1 mutants can induce specific abnormalities of the VDJ recombination process.
116 citations
TL;DR: Chronic-plus-binge ethanol feeding of mice, which mimics the drinking pattern of patients with AH, produced severe ASH and mild fibrosis and microarray analyses revealed similar alterations in expression of many hepatic genes in ethanol-fed mice and humans with ASH, including up-regulation of mouse Fsp27 (also called Cidec) and human CIDEC.
116 citations
Emory University1, Samsung Medical Center2, Washington University in St. Louis3, Duke University4, University of Lausanne5, Hebron University6, Seoul National University Bundang Hospital7, Pontifícia Universidade Católica do Rio Grande do Sul8, Aix-Marseille University9, Bristol-Myers Squibb10, Yonsei University11
TL;DR: In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability as discussed by the authors.
Abstract: PURPOSEIn extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase...
116 citations
Authors
Showing all 2723 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| José Baselga | 156 | 707 | 122498 |
| M. I. Martínez | 134 | 1251 | 79885 |
| Josep Tabernero | 111 | 803 | 68982 |
| Jordi Rello | 103 | 694 | 35994 |
| Xavier Montalban | 95 | 762 | 52842 |
| James M. Downey | 91 | 381 | 29506 |
| Enriqueta Felip | 83 | 622 | 53364 |
| Joaquim Bellmunt | 82 | 660 | 41472 |
| Joan Montaner | 80 | 489 | 22413 |
| Marc Miravitlles | 76 | 651 | 25671 |
| David H. Salat | 75 | 241 | 36779 |
| Eduard Gratacós | 75 | 531 | 20178 |
| Alex Rovira | 74 | 356 | 19586 |
| Ramon Bataller | 72 | 283 | 19316 |
| Maria Buti | 71 | 493 | 26596 |